



Fig. S2 Kaplan Meier survival analyses in the cohort not receiving (neo)adjuvant chemotherapy. Invasive disease-free survival (IDFS), overall survival (OS) and distant relapse-free interval (DRFI) according to PD-L1 SP142 immune cell staining (IC+) in panel (A), in panel (B) for 22C3 combined positive score (CPS) at a threshold of 10, in (C) according to 22C3 CPS at a threshold of 1 and in (D) for 22C3 IC+.